

**Table Of Content**

**Journal Cover** ..... 2

**Author[s] Statement** ..... 3

**Editorial Team** ..... 4

**Article information** ..... 5

    Check this article update (crossmark) ..... 5

    Check this article impact ..... 5

    Cite this article ..... 5

**Title page** ..... 6

    Article Title ..... 6

    Author information ..... 6

    Abstract ..... 6

**Article content** ..... 7

---

# Academia Open



*By Universitas Muhammadiyah Sidoarjo*

---

## Originality Statement

The author[s] declare that this article is their own work and to the best of their knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the published of any other published materials, except where due acknowledgement is made in the article. Any contribution made to the research by others, with whom author[s] have work, is explicitly acknowledged in the article.

## Conflict of Interest Statement

The author[s] declare that this article was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Copyright Statement

Copyright © Author(s). This article is published under the Creative Commons Attribution (CC BY 4.0) licence. Anyone may reproduce, distribute, translate and create derivative works of this article (for both commercial and non-commercial purposes), subject to full attribution to the original publication and authors. The full terms of this licence may be seen at <http://creativecommons.org/licenses/by/4.0/legalcode>

## EDITORIAL TEAM

### Editor in Chief

Mochammad Tanzil Multazam, Universitas Muhammadiyah Sidoarjo, Indonesia

### Managing Editor

Bobur Sobirov, Samarkand Institute of Economics and Service, Uzbekistan

### Editors

Fika Megawati, Universitas Muhammadiyah Sidoarjo, Indonesia

Mahardika Darmawan Kusuma Wardana, Universitas Muhammadiyah Sidoarjo, Indonesia

Wiwit Wahyu Wijayanti, Universitas Muhammadiyah Sidoarjo, Indonesia

Farkhod Abdurakhmonov, Silk Road International Tourism University, Uzbekistan

Dr. Hindarto, Universitas Muhammadiyah Sidoarjo, Indonesia

Evi Rinata, Universitas Muhammadiyah Sidoarjo, Indonesia

M Faisal Amir, Universitas Muhammadiyah Sidoarjo, Indonesia

Dr. Hana Catur Wahyuni, Universitas Muhammadiyah Sidoarjo, Indonesia

Complete list of editorial team ([link](#))

Complete list of indexing services for this journal ([link](#))

How to submit to this journal ([link](#))

**Article information**

**Check this article update (crossmark)**



**Check this article impact (\*)**



**Save this article to Mendeley**



(\*) Time for indexing process is various, depends on indexing database platform

## **Achievements and Prospects of Treatment of Chronic Gastritis**

### *Pencapaian dan Prospek Pengobatan Gastritis Kronis*

**Ochilov Alisher Kamilovich, alimed@inbox.ru, (1)**

*Bukhara State Medical Institute Abu Ali ibn Sino, Uzbekistan*

**Ochilova Gulrukh Saidovna, alimed@inbox.ru, (0)**

*Bukhara State Medical Institute Abu Ali ibn Sino, Uzbekistan*

<sup>(1)</sup> Corresponding author

#### **Abstract**

This article presents a comprehensive examination of the influence of genetic factors on individual drug response in pharmacotherapy, emphasizing the potential for personalized medicine and minimizing the risk of adverse drug reactions. The study aims to explore the goals, methods, results, and implications of incorporating modern approaches to personalized pharmacotherapy. By understanding the role of genetics in drug response, physicians and researchers can envision improved methods of tailoring treatments to individual patients, ultimately reducing the likelihood of side effects and optimizing therapeutic outcomes. This article highlights the promising prospects of personification of pharmacotherapy, highlighting the potential for revolutionizing medical practice and enhancing patient care.

#### **Highlights:**

- **Influence of genetic factors:** This article examines the significant impact of genetic factors on an individual's response to drugs in pharmacotherapy, highlighting the importance of understanding genetic variations for personalized treatment.
- **Personalized medicine potential:** The study explores the potential for personalized pharmacotherapy, aiming to tailor drug treatments based on an individual's genetic profile, with the goal of minimizing side effects and optimizing therapeutic outcomes.
- **Enhancing patient care:** By considering genetic factors, healthcare professionals can anticipate a reduction in adverse drug reactions and improve treatment effectiveness, leading to enhanced patient care and better treatment outcomes.

**Keywords:** Genetic factors, personalized pharmacotherapy, individual drug response, side effects, treatment outcomes.

Published date: 2023-01-12 00:00:00

## Introduction

Treatment of chronic gastritis is not an easy task for both the doctor and the patient. First of all, it requires considerable time, perseverance and endurance from both, and besides, sometimes a certain sanatorium-type environment [1,3,19].

The effectiveness of therapy depends not only on the knowledge of the doctor, his treatment tactics, not excluding the interaction of drugs, their pharmacokinetics and pharmacodynamics, but also on the adherence of patients, the characteristics of their genetic apparatus, which is not a little important in achieving the effect of the applied pharmacotherapy [2, 5, 9].

It is known that in the complex therapy of chronic gastritis, the diet occupies one of the most important places [15], therefore, in chronic gastritis with secretory insufficiency, diet No. 2 is selected, which consists of dishes sparing the mucous membranes of the stomach and stimulating gastric secretion [4, 6, 11]. Depending on the main clinical manifestations, therapeutic nutrition is selected individually.

Pharmacotherapy chronic gastritis is selected depending on the form of the disease, where the main role is played by the etiology, pathogenesis, clinical morphological picture of the disease. The tactics of treatment of chronic gastritis associated with *H.pylori* and non-associated are significantly different, but in both cases pharmacotherapy is selected based on the severity and activity of the pathological process with gastric mucosa, intestinal condition, as well as the activity of compensatory capabilities of the liver, pancreas and hepatobiliary system [5, 7].

Clinicians for the treatment of chronic gastritis prefer drugs from the group of PPIs, such as omeprazole, pantoprazole, lansoprazole, esomeprazole, as well as a drug from the group of antagonists of H-2-histaminoreceptors - famotidine (kvamatel), ranitidine, etc., selective M-cholinoblocking agents of the type - pirenzepine (gastrocepin), etc., drugs from the group antacids - almagel, its analogue almalel A, gastrogel, gelusil, phosphalyugel and the drug maalox, as well as prokinetics - for example, domperidone, etc. drugs [8, 10, 13].

The principles of pharmacotherapy for chronic gastritis may be standard, but the treatment of the disease cannot be the same for all patients, it must be personalized. This approach is based on the genetic characteristics of the patient.

Based on the above, it should be noted that the effectiveness of HG pharmacotherapy is directly influenced by the intensity of metabolism of first-line drugs - proton pump inhibitors, where the genetic feature of the patient plays an important role as a source of interindividual differences in the metabolic processes of pharmacological substances [12, 14, 18].

A number of studies are being conducted in the world aimed at studying the features and influence of polymorphisms of the CYP2C19 gene on the course and effectiveness of treatment of a number of diseases where this gene plays a particularly important role [6, 17]. In this regard, the main tasks of this direction are an in-depth analysis of the occurrence of genotypes of this gene, the peculiarities of the course of diseases depending on the genetic affiliation of the patient, their impact on the results and effectiveness of treatment and, depending on this, the improvement of pharmacotherapy [16, 20].

**The purpose of the study** The aim is to evaluate the effectiveness of treatment and determine the possibilities of personal pharmacotherapy by identifying the features of the occurrence of variants of the CYP2C19 gene genotype in patients with chronic gastritis.

## Methods

In accordance with the objectives of the dissertation, a comprehensive examination was carried out in the scientific and genetic laboratory at the Olympic Committee of Uzbekistan, 80 unrelated patients with HG who were on inpatient treatment and observation at the Regional Multidisciplinary Clinical Hospital of the city of Bukhara and at Mohi Hossa. These patients made up the main comparison group.

The control group consisted of 20 healthy unrelated and without a history of gastrointestinal pathology persons who corresponded by gender and age to the examined group of patients with HG.

The age of patients with HG ranged from 15 to 79 years, men were 27 (33.8%), women - 53 (66.2%), that is, women significantly prevailed among patients with HG.

To achieve the goal and fulfill the tasks set, the following methods were used: general clinical examination of patients, laboratory-instrumental, molecular-genetic research methods, as well as methods of statistical processing of the data obtained.

## Results

it is known that the pharmacotherapy of HG varies depending on the form of the course and type of the disease, which serves to restore the structure and function of the stomach. However, the result of treatment may not always be what we would like. As a result of the selected pharmacotherapy by types of HG, the following results were obtained (Fig. 1):

HG type A - recovery - 57%, improvement - 43%, without improvement, deterioration and complications were not observed;

HG type B - recovery - 41%, improvement - 33%, without improvement - 10%, deterioration - 10%, complications - 5%;

HG type C - recovery - 33%, improvement - 33%, without improvement - 20%, deterioration - 7%, complications - 7%.

Thus, the pharmacotherapy of HG has different effects depending on the type of HG. Thus, HG type is treatable and there were no worsening and complications of the disease; whereas after pharmacotherapy, HG type C is effective only in 1/3 of patients and it should be noted that there are cases of complications and worsening of the disease. Adequate efficacy of pharmacotherapy was not observed in the type of HG. After this therapy, 1/10 of the patients' condition worsened and 1/20 of the patients had complications of the disease.

**Figure 1.** Treatment results depending on the type of chronic gastritis ( % )

In the selected group of patients with HG, regardless of the type of disease, the frequency of occurrence of variants of the genotypes of the CYP2C19 (G681A) gene was studied by gender division, the results of which showed that the homozygous "wild" allelic genotype GG (CYP2C19\*1/\*1) the CYP2C19 (G681A) gene is found in more than 66% of women with HG, whereas in men with a similar diagnosis, this variant of the genotype is 2 times less common (Table 1).

The studied genes	Variants of genotypes	Study groups							
		Control (n=20)				Experience (n=80)			
		Man		Woman		Man		Woman	
		n	%	n	%	n	%	n	%
CYP 2C19 G681A	A/A	-	-	-	-	2	100,0		
	G/G	7	35,00	43,75	9	56,25	18	33,33	36
	G/A	2	10,00	50,00	2	50,00	9	37,50	15

**Table 1.** Gender characteristics of the frequency of genotype distribution of the allele variant G681A of the gene CYP 2C19 in patients with H G

Heterozygous "wild" and "mutant" GA allelic genotype (CYP2C19\*1/\*2) it was detected in more than 62% of women with HG, but in male patients this variant of the genotype occurs in 37% of cases. It should be noted that the "mutant" allele genotype AA (CYP2C19\*2/\*2) among all variants of the genotypes of the CYP2C19 gene, it is rare - only in women with HG, and it has not been detected in male patients. The same genotype was not determined in healthy men and women from the control group.

Thus, chronic gastritis is 1.5 times more common in women, as well as the "mutant" allele genotype AA (CYP2C19\*2/\*2) the CYP2C19(G681A) gene does not occur in male patients. Determination of the genotypic affiliation of patients with HG makes it possible to personalize pharmacotherapy.

## Conclusions

Therefore, a personalized approach to each patient in the selection of drugs for treatment is the most optimal pharmacotherapy tactic. Such an individual approach should be based on the genetic characteristics of the patient



according to the drugs selected for treatment. Methods of genotyping patients provides an increase in the effectiveness and safety of pharmacotherapy, which is the main task of clinical pharmacology, therapy and medicine in general.

## References

1. Isakov, V.A. Farmakogeneticheskiy analiz metabolizma i klinicheskoy effektivnosti ingibitorov protonnogo nasosa/ V.A.Isakov//Klin. farmakol. ter. 2003. № 1. S. 32 - 37.
2. Kitaeva E. YU., Shprax V.V., Mirzaev K.B., Rijikova K.A., Shuev G.N., Sozaeva J.A., Pimenova YU.A., Kogay V.V., Sechev D.A.// Chastota polimorfizmov genov CYP2C19 i ABCB1, assotsirovannix s izmeneniem antiagregantnogo deystviya klopidogrela, u russkix i buryat. Sibirskoe meditsinskoe obozrenie. 2018 №3 43-50 S.
3. Ochilov A.K., G.S.Ochilova. "Znachenie gena CYP2C19 v farmakoterapii pri xronicheskix gastritax» Problemi biologii i meditsini, 2019, № 4 (113)
4. Ochilov A.K., Musaeva D.M. "Lechenie xronicheskogo gastrita v zavisimosti ot allelnix variantov gena CYP2C19» Mejdunarodnoy nauno- prakticheskoy onlayn- konferensii «Aktualnie voprosi meditsinskoj nauki v XXI veke» g.Tashkent, 25.04.2019g.
5. Ochilov A.K., Ochilova G.S. Klinicheskaya znachimost polimorfizmov gena CYP2C19 // Universitetskaya nauka: vzglyad v budуще. Sbornik nauchnix trudov po materialam Mejdunarodnoy nauchnoy konferensii, posvyashchennoy 85-letiyu Kurskogo gosudarstvennogo meditsinskogo universiteta (7 fevralya 2020 goda) Tom I. 2020. 376-379 S.
6. Klichova F.K., Ochilova G.S. Sbornik tezisov II Vserossiyskoj nauchno- prakticheskoy konferensii s mejdunarodnim uchastiem. Bezopasnost farmakoterapii: NOLI NOCERE! g. Kazan, 16 maya 2019 g.
7. Musaeva D.M., Ochilova G.S. "Znachenie gena MDR-1 v farmakoterapii pri xronicheskix gastritax» Problemi biologii i meditsini, 2019, № 4 (113)
8. Musaeva D.M., Ochilova G.S. "Surunkali gastritni davolashda MDR-1 allel variantlarining ahamiyati» Materiali mejdunarodnoy nauchno- prakticheskoy onlayn-konferensii «Aktualnie voprosi meditsinskoj nauki v XXI veke» g.Tashkent, 25.04.2019g.
9. Musaeva D.M., Ochilova G.S. "Surunkali gastritni davolashda MDR-1 allel variantlarining ahamiyati» Materiali mejdunarodnoy nauchno- prakticheskoy onlayn-konferensii «Aktualnie voprosi meditsinskoj nauki v XXI veke» g.Tashkent, 25.04.2019g.
10. Musaeva D.M., Ochilov A.K., Ochilova G.S. Korreksiya farmakometaboliziruyushey funksii pecheni antioksidantami //Dostizheniya nauki i obrazovaniya. - 2018. - №. 10 (32).
11. Musaeva D. M., Klichova F. K., Ochilova G. S. Vliyanie GAMK-mimetikov na farmakodinamiku etaminala natriya pri eksperimentalnom toksicheskom gepatite //Nauchniy jurnal. - 2018. - №. 8 (31).
12. Musaeva D. M., Samadov B. SH., Ochilova G. S. Gepatotoprotektoornoie vliyanie fenobarbitala pri eksperimentalnom toksicheskom gepatite. 341-344 s.
13. Ochilov A.K., Musaeva D.M. Osobennosti gena CYP2S19 dlya individualizitsii farmakoterapii. //Noviy den v meditsine 1 (29) 2020. 65-68 s.
14. Ochilova G. S., Musaeva D. M. Vliyanie polimarfizma gena MDR-1 na effektivnost lecheniya xronicheskogo gastrita. //Noviy den v meditsine 1 (29) 2020. 309-312 s.
15. Arvanitidis, K. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population // K. Arvanitidis, G. Ragia, M. Iordanidou et al.//Fundam. Clin. Pharmacol. 2007. Vol. 21 №4. P. 419 - 426.
16. Arvanitidis, K. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population // K. Arvanitidis, G. Ragia, M. Iordanidou et al.//Fundam. Clin. Pharmacol. 2007. Vol. 21 №4. P. 419 - 426.
17. Efrén Martínez-Quintana, Fayna Rodríguez-González, José María Medina-Gil, Paloma Garay-Sánchez, Antonio Tugores // Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con síndrome coronario agudo. Medicina Clínica. Volume 149. Issue 6. 2017. Pages 235-239.
18. Kim K.A., Park P.W., Park J.Y. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects//Br. J. Clin.Pharmacol. 2007, Jan. Vol.63, №1. P. 53-58.
19. Kim R. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev., 2012, 34, 47-54.
20. Kuzuya T., Kobayashi T., Moriyama N., Nagasaka T., Yokoyama I., Uchida K., Nakao A., Nabeshima T. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients//Transplantation. 2003. Vol.76, №5.P. 865-868.